Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.64 |
| ▸ | IDE | P14735 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | AANAT | Q16613 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792022 | 0.94 | MEN1 (0.66) | MEN1KMT2AMTNR1AHPGDRECQL | |
| SCHEMBL18607543 | 0.87 | MEN1 (0.77) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| SCHEMBL16792193 | 0.87 | LMNA (0.57) | MEN1KMT2AMTNR1AALDH1A1MAPT | |
| SCHEMBL16792198 | 0.83 | MEN1 (0.58) | MEN1KMT2AMTNR1ACYP1A2CYP2D6 | |
| SCHEMBL5578012 | 0.83 | MEN1 (0.83) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| SCHEMBL18607486 | 0.82 | MEN1 (0.77) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| SCHEMBL7972523 | 0.82 | MEN1 (0.81) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| SCHEMBL6646410 | 0.82 | MTNR1A (0.88) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| Hydrochloric Acid SCHEMBL7960692 | 0.81 | MEN1 (0.79) | MEN1KMT2AMTNR1AIDECYP1A2 | |
| SCHEMBL7974250 | 0.80 | MEN1 (0.77) | MEN1KMT2AMTNR1AIDECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089349-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015084721-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | MEN1 304/4885KMT2A 4161/4885MTNR1A 3430/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | MEN1 660/4885KMT2A 4620/4885MTNR1A 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.